CollPlant Biotechnologies
CLGN
18 hedge funds and large institutions have $10.9M invested in CollPlant Biotechnologies in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 2 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0% more funds holding
Funds holding: 18 → 18 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.48% less ownership
Funds ownership: 14.32% → 13.84% (-0.48%)
17% less capital invested
Capital invested by funds: $13.1M → $10.9M (-$2.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Shay Capital
New York
|
+$98.2K |
| 2 |
BFEC
Benjamin F. Edwards & Company
St. Louis,
Missouri
|
+$47.7K |
| 3 |
SDJVC
St. Denis J. Villere & Co
New Orleans,
Louisiana
|
+$26K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$25.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$9.46K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
-$270K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$50.9K |
| 3 |
PA
Parallel Advisors
San Francisco,
California
|
-$29.7K |
| 4 |
SQA
Simon Quick Advisors
Morristown,
New Jersey
|
-$24.3K |
| 5 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
-$687 |
CLGN Hedge Fund Activity: Q1 2023 in Review
18 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q1 2023, worth a combined $10.9M — down 17% from $13.1M a quarter earlier.
Fund positioning in CLGN was balanced in Q1 2023: 2 funds opened new positions, 2 closed out, 5 added to existing stakes and 4 trimmed.
The largest buyer was Shay Capital, opening a new position worth an estimated $98.2K. The largest seller was Roumell Asset Management, cutting an estimated $270K.
- 18 institutional investors held CollPlant Biotechnologies (CLGN) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $10.9M of CollPlant Biotechnologies stock for Q1 2023, down 17% quarter-over-quarter.
- 2 funds opened new CollPlant Biotechnologies positions in Q1 2023 and 2 closed out, a net change of 0 holders.
- The largest CollPlant Biotechnologies buyer in Q1 2023 was Shay Capital, an estimated $98.2K added.
- The largest CollPlant Biotechnologies seller in Q1 2023 was Roumell Asset Management, an estimated $270K sold.
Based on aggregated 13F filings for Q1 2023.